Chemical Structure : Oprozomib
CAS No.: 935888-69-0
Catalog No.: PC-42896Not For Human Use, Lab Use Only.
Oprozomib (ONX-0912, PR-047) is a potent, orally bioavailable proteasome inhibitor that inhibits chymotrypsin-like (CT-L) activity of 20S proteasome β5/LMP7 with IC50 of 36/82 nM.
Packing | Price | Stock | Quantity |
---|---|---|---|
5 mg | $88 | In stock | |
10 mg | $128 | In stock | |
25 mg | $218 | In stock | |
50 mg | $368 | In stock | |
100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Oprozomib (ONX-0912, PR-047) is a potent, orally bioavailable proteasome inhibitor that inhibits chymotrypsin-like (CT-L) activity of 20S proteasome β5/LMP7 with IC50 of 36/82 nM.
Oprozomib triggers apoptosis in MM cells, associated with PARP cleavage and caspase activation, causes in vitro and in vivo cytotoxicity in multiple myeloma.
Oprozomib also enhances anti-MM activity of bortezomib, lenalidomide dexamethasone, or pan-histone deacetylase inhibitor.
M.Wt | 532.6092 | |
Formula | C25H32N4O7S | |
Appearance | Solid | |
Storage |
|
|
Solubility |
DMSO: ≥ 50 mg/mL |
|
Chemical Name/SMILES |
L-Serinamide, O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]- |
1. Verbrugge SE, et al. J Pharmacol Exp Ther. 2012 Apr;341(1):174-82.
2. Chauhan D, et al. Blood. 2010 Dec 2;116(23):4906-15.
3. Zhou HJ, et al. J Med Chem. 2009 May 14;52(9):3028-38.
4. Hurchla MA, et al. Leukemia. 2013 Feb;27(2):430-40.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright